Need professional-grade analysis? Visit stockanalysis.com
$332.17M
N/A
N/A
N/A
Palisade Bio Inc (PALI) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.34, down 16.43% from the previous close.
Over the past year, PALI has traded between a low of $0.54 and a high of $2.80. The stock has gained 216.2% over this period. It is currently 16.4% below its 52-week high.
Palisade Bio Inc has a market capitalization of $332.17M.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Side-by-side comparison against top Healthcare peers.